



# Viz Cardiac Amyloidosis™



AI Care Pathway to Support Earlier Clinical Evaluation and Care Coordination

## Streamlined Cardiac Care Coordination



## Reach & Impact

**2,000**  
Hospitals<sup>1</sup>

**75,000+**  
Clinician Users<sup>2</sup>

**>10k**  
Identified &  
Activated Patients<sup>2</sup>

**Up to 6x**  
Increase in Identified  
Suspected Cases<sup>3</sup>

## Secure & Trusted



1. Viz company data as of March 2026 2. Viz HCM Tableau Dashboard as of May 2025 3. Data to be presented at a large medical conference in 2026 (temporarily blinded)

### What Viz Can Bring to Providers

#### Clinicians



##### Automated detection from routine echo

Flagged suspected cardiac amyloidosis off echocardiogram



##### Chart summarization & guideline-based recommendations

Contextually relevant EHR summaries & next steps



##### Seamless care coordination

Chat the full care team, refer, and activate for follow-up & treatment

#### Hospital Systems



##### Supports quality initiatives and earlier case identification

Earlier ID, less leakage, service-line credibility



##### Supporting Near-Term Operational and Economic Value Drivers


Help reduce missed or delayed diagnoses without increasing unnecessary utilization



##### Enterprise workflow lift

Auto-runs on every echo with audit trail and coordination

### Embedded Within Clinical Workflow



Seamlessly Integrated

Echo | ECG | Us2.ai™ | EHR | PACS